Abbott Laboratories [NYSE: ABT] closed the trading session at $107.83 on 12/28/22. The day’s price range saw the stock hit a low of $107.735, while the highest price level was $110.10. The company report on December 27, 2022 that Abbott To Upgrade 75 Primary Health Centres Across India, Providing Quality, Accessible Care to 2.5 Million People.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Abbott has partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine states in India.
The stocks have a year to date performance of -23.38 percent and weekly performance of 1.26 percent. The stock has been moved at -1.16 percent over the last six months. The stock has performed 2.32 percent around the most recent 30 days and changed 9.23 percent over the most recent 3-months.
If compared to the average trading volume of 5.79M shares, ABT reached to a volume of 3260914 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $117.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 26, 2022. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on October 18, 2022, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $110, while Jefferies analysts kept a Hold rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.04, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 4.17. The Price to Book ratio for the last quarter was 5.30, with the Price to Cash per share for the same quarter was set at 5.69. Price to Free Cash Flow for ABT in the course of the last twelve months was 35.71 with Quick ratio for the last quarter at 1.40.
ABT stock trade performance evaluation
Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.26. With this latest performance, ABT shares gained by 2.32% in over the last four-week period, additionally sinking by -1.16% over the last 6 months – not to mention a drop of -23.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 54.30, with the RSI for the last a single of trading hit 52.30, and the three-weeks RSI is set at 54.63 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 103.66, while it was recorded at 108.15 for the last single week of trading, and 108.61 for the last 200 days.
Abbott Laboratories [ABT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +21.36 and a Gross Margin at +53.89. Abbott Laboratories’s Net Margin is presently recorded at +16.35.
Return on Equity for this stock inclined to 20.53, with Return on Assets sitting at 9.53.
Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.90.
Earnings per share (EPS) analysis for Abbott Laboratories [ABT] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 8.30%.
Abbott Laboratories [ABT]: Insider Ownership positions
There are presently around $140,177 million, or 76.20% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 154,563,421, which is approximately 1.319% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 133,336,257 shares of the stock with an approximate value of $14.38 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $8.5 billion in ABT stock with ownership of nearly -1.611% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,207 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 41,805,931 shares. Additionally, 1,141 investors decreased positions by around 40,519,135 shares, while 443 investors held positions by with 1,217,657,035 shares. The mentioned changes placed institutional holdings at 1,299,982,101 shares, according to the latest SEC report filing. ABT stock had 101 new institutional investments in for a total of 8,868,290 shares, while 155 institutional investors sold positions of 3,257,178 shares during the same period.